title: Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.
abstract: Onychomycosis is a stubborn fungal infection of the nails that can be difficult to effectively manage. One of the challenges with topical therapies is penetrating the nail plate to reach the site of infection. As the first antifungal in a boron-containing class of drugs with a novel mechanism of action, tavaborole is able to penetrate the nail plate more effectively than ciclopirox and amorolfine lacquers. In Phase II/III clinical trials, tavaborole was shown to be safe and clinically effective. Tavaborole 5% solution was approved by the US FDA for the treatment of toenail onychomycosis in July 2014 and is an important addition to the topical treatment arsenal against this stubborn infection.
authors.affiliation: Wayne State University, Detroit, MI, USA; Mediprobe Research Inc., London, ON, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Gupta
authors.affiliation: Mediprobe Research Inc., London, ON, Canada.
authors.forename: K A
authors.initials: KA
authors.lastname: Foley
authors.affiliation: Mediprobe Research Inc., London, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
mesh_terms: D000279:Administration, Cutaneous; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001896:Boron Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004339:Drug Compounding; D005533:Foot Dermatoses / Q000188:drug therapy*; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; C512998:tavaborole